» Articles » PMID: 17239601

Selective L-nitroargininylaminopyrrolidine and L-nitroargininylaminopiperidine Neuronal Nitric Oxide Synthase Inhibitors

Overview
Journal Bioorg Med Chem
Specialties Biochemistry
Chemistry
Date 2007 Jan 24
PMID 17239601
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Selective inhibition of the localized excess production of NO by neuronal nitric oxide synthase (nNOS) has been targeted as a potential means of treating various neurological disorders. Based on observations from the X-ray crystal structures of complexes of nNOS with two nNOS-selective inhibitors, (4S)-N-{4-amino-5-[(2-amino)ethylamino]pentyl}-N'-nitroguanidine (L-Arg(NO2)-L-Dbu-NH2 (1) and 4-N-(Nomega-nitro-L-argininyl)-trans-4-amino-L-proline amide (2), a series of descarboxamide analogues was designed and synthesized (3-7). The most potent compound was aminopyrrolidine analogue 3, which exhibited better potency and selectivity for nNOS than parent compound 2. In addition, 3 provided higher lipophilicity and a lower molecular weight than 2, therefore having better physicochemical properties. Nalpha-Methylated analogues (8-11) also were prepared for increased lipophilicity of the inhibitors, but they had 4- to 5-fold weaker binding affinity compared to their parent compounds.

Citing Articles

Clickable Polyprolines from Azido-proline -Carboxyanhydride.

Detwiler R, McPartlon T, Coffey C, Kramer J ACS Polym Au. 2023; 3(5):383-393.

PMID: 37841952 PMC: 10571246. DOI: 10.1021/acspolymersau.3c00011.


-Ethyl-Isothiocitrullin-Based Dipeptides and 1,2,4-Oxadiazole Pseudo-Dipeptides: Solid Phase Synthesis and Evaluation as NO Synthase Inhibitors.

Mauchauffee E, Leroy J, Chamcham J, Ejjoummany A, Maurel M, Nauton L Molecules. 2023; 28(13).

PMID: 37446746 PMC: 10343299. DOI: 10.3390/molecules28135085.


Automated Radiosynthesis of - and -4-[F]Fluoro-l-proline Using [F]Fluoride.

Morgan T, Riley L, Tavares A, Sutherland A J Org Chem. 2021; 86(20):14054-14060.

PMID: 33913318 PMC: 8524414. DOI: 10.1021/acs.joc.1c00755.


Development of nitric oxide synthase inhibitors for neurodegeneration and neuropathic pain.

Mukherjee P, Cinelli M, Kang S, Silverman R Chem Soc Rev. 2014; 43(19):6814-38.

PMID: 24549364 PMC: 4138306. DOI: 10.1039/c3cs60467e.


Arginine-based inhibitors of nitric oxide synthase: therapeutic potential and challenges.

Vitecek J, Lojek A, Valacchi G, Kubala L Mediators Inflamm. 2012; 2012:318087.

PMID: 22988346 PMC: 3441039. DOI: 10.1155/2012/318087.


References
1.
Erdal E, Litzinger E, Seo J, Zhu Y, Ji H, Silverman R . Selective neuronal nitric oxide synthase inhibitors. Curr Top Med Chem. 2005; 5(7):603-24. DOI: 10.2174/1568026054679317. View

2.
Stuehr D . Enzymes of the L-arginine to nitric oxide pathway. J Nutr. 2004; 134(10 Suppl):2748S-2751S. DOI: 10.1093/jn/134.10.2748S. View

3.
Griffith O, Stuehr D . Nitric oxide synthases: properties and catalytic mechanism. Annu Rev Physiol. 1995; 57:707-36. DOI: 10.1146/annurev.ph.57.030195.003423. View

4.
Moncada S, Higgs A, Furchgott R . International Union of Pharmacology Nomenclature in Nitric Oxide Research. Pharmacol Rev. 1997; 49(2):137-42. View

5.
Gerber N, Rodriguez-Crespo I, Nishida C, Ortiz de Montellano P . Active site topologies and cofactor-mediated conformational changes of nitric-oxide synthases. J Biol Chem. 1997; 272(10):6285-90. DOI: 10.1074/jbc.272.10.6285. View